Form 8-K/A

8-K/A — Transcode Therapeutics, Inc.

Accession: 0001104659-26-065959

Filed: 2026-05-26

Period: 2026-05-19

CIK: 0001829635

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Documents

8-K/A — tm2615597d1_8ka.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K/A — FORM 8-K/A

8-K/A (Primary)

Filename: tm2615597d1_8ka.htm · Sequence: 1

false

0001829635

2026-05-19

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

Amendment No. 1

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported): May 19, 2026

TRANSCODE

THERAPEUTICS, INC.

(Exact name of registrant as specified in its

charter)

Delaware

001-40363

81-1065054

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

TransCode

Therapeutics, Inc.

Liberty Square, #2382

Boston, Massachusetts

02109

(Address

of principal executive offices, including zip code)

(857)

837-3099

(Registrant’s

telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

Title of each class

Trading symbol(s)

Name of each exchange on which

registered

Common

Stock, par value $0.0001 per share

RNAZ

The Nasdaq

Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company x

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Explanatory note

TransCode Therapeutics, Inc., a Delaware corporation

(the “Company”), is filing this Amendment No. 1 (the “Amendment No.1”) to its Current Report on Form 8-K originally

filed with the Securities and Exchange Commission (the “SEC”) on May 22, 2026 (the “Prior Form 8-K”) to amend

and restate the disclosure previously included therein to provide additional information regarding the Company’s plan to regain

compliance with Nasdaq Listing Rule 5550(b)(1), and to check the box indicating that this Current Report on Form 8-K includes soliciting

material pursuant to Rule 14a-12 under the Exchange Act.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On May 19, 2026, TransCode Therapeutics,

Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of

the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’

equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the

Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”).

The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, reported stockholders’ equity of $1,251,427,

which is below the Stockholders’ Equity Requirement.

This Nasdaq notification has no immediate effect

on the Company’s continued listing on the Nasdaq Capital Market. In accordance with Nasdaq rules, the Company has been provided

45 calendar days, or until July 3, 2026, to submit a plan to regain compliance (the “Compliance Plan”).

The

Company expects to include in its Compliance Plan that the Company expects to regain compliance with the Stockholders’ Equity Requirement

after stockholder approval of the conversion of the Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (“Series

A Preferred Stock”) is obtained at its upcoming meeting of the stockholders. A preliminary proxy for such meeting was filed

with the SEC on May 8, 2026. As previously disclosed in the Company’s Quarterly Report on Form 10-Q for the period ended March

31, 2026, in the event the Company is unable to obtain an affirmative stockholder vote by December 31, 2026, to permit conversion of the

Series A Preferred Stock, each holder of Series A Preferred Stock will be entitled to elect, at the holder’s option, to have their

shares of Series A Preferred Stock redeemed by the Company for an amount equal to the estimated fair value of the shares of Series A Preferred

Stock held by such holder at the time of redemption. Due to this redemption feature, as of March 31, 2026, the Series A Preferred Stock

was classified within temporary equity on the Company’s consolidated balance sheet. If stockholder approval has been obtained, the

Series A Preferred Stock will be re-classified as equity on the Company’s consolidated balance sheet, and the Company will then

regain compliance with the Stockholders’ Equity Requirement.

The Staff may grant an extension of 180 calendar

days from the date of the deficiency letter to regain compliance with the Stockholders’ Equity Requirement. If the Staff does not

accept the Compliance Plan, the Staff will provide written notification to the Company that the Compliance Plan has been rejected. At

that time, the Company may appeal the Staff’s determination to a Nasdaq Hearings Panel.

Readers are cautioned that the Staff may not accept

the Company’s plan to regain compliance with the Stockholders’ Equity Requirement. Further, even if the Company’s Compliance

Plan is accepted, the Company may be unable to evidence compliance with the Stockholders’ Equity Requirement during any extension

period that the Staff may grant, either through additional equity financings, improved operational results or shareholder actions. If

the Staff does not accept the Company’s Compliance Plan or if the Company is unable to regain compliance within any extension period

granted by the Staff, the Staff would be required to issue a delisting determination. The Company would at that time be entitled to request

a hearing before a Nasdaq Hearings Panel to present its Compliance Plan and to request a further extension period to regain compliance.

The request for a hearing would stay any delisting action by the Staff. No assurances can be given that the Company’s efforts to

comply with the Stockholders’ Equity Requirement will be successful. Any delisting of the Company’s common stock from Nasdaq

would have a material adverse effect on the Company, its operations and reputation, and on the value of the Company’s shares.

Forward Looking Statements

Any statements in this Current Report on Form

8-K about the future expectations, plans and prospects of the Company, including without limitation, statements regarding: the Company’s

plan to regain compliance with Nasdaq Listing Rules, timing of the stockholder meeting, ability to obtain stockholder approval of the

conversion of Preferred Stock and other statements containing the words “anticipate,” “believe,” “continue,”

“could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,”

“plan,” “potential,” “predict,” “project,” “should,” “target,”

“would” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation

Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various

important factors, including, but not limited to those set forth under the caption “Risk Factors” in the Company’s most

recent Annual Report on Form 10-K filed with the SEC, as supplemented by its subsequent Quarterly Reports on Form 10-Q, and in other filings

made with the SEC. In addition, any forward-looking statements included in this Current Report on Form 8-K represent the Company’s

views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company specifically

disclaims any intention to update any forward-looking statements included in this Current Report on Form 8-K unless required by law.

Important Information About the Conversion

of Preferred Stock and Where to Find It

The Company expects to file a proxy statement

with the SEC relating to the approval by the Company’s stockholders of the conversion of the shares of Series A Preferred Stock

and Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (“Series B Preferred Stock”) into shares

of Common Stock in accordance with the rules of the Nasdaq Stock Market LLC and (ii) the approval of a “change of control”

under Nasdaq Listing Rules 5110 and 5635(b), among other matters. The definitive proxy statement will be sent to all Company stockholders.

Before making any voting decision, investors and securityholders of the Company are urged to read the proxy statement and all other relevant

documents filed or that will be filed with the SEC in connection with the proposals included in the proxy statement as they become available

because they will contain important information about the conversion of the Series A Preferred Stock and Series B Preferred Stock, the

related transactions and the other proposals to be voted upon. Investors and securityholders will be able to obtain free copies of the

proxy statement and all other relevant documents filed or that will be filed with the SEC by the Company through the website maintained

by the SEC at www.sec.gov.

Participants in Solicitation

The Company and its directors, executive officers

and employees may be deemed to be participants in the solicitation of proxies in respect of the conversion of the Series A Preferred Stock

and Series B Preferred Stock. Information regarding the Company’s directors and executive officers is available in the Company’s

Amended Annual Report on Form 10-K/A for the year ended December 31, 2025, filed with the SEC on April 30, 2026, under “Item

10 Directors, Executive Officers and Corporate Governance” and “Item 12 Security Ownership of Certain Beneficial Owners

and Management and Related Stockholder Matters.” Information regarding the persons who may, under the rules of the SEC, be deemed

participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will

be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available.

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSCODE THERAPEUTICS, INC.

By:

/s/ Thomas A. Fitzgerald

Name:

Thomas A. Fitzgerald

Title:

Chief Financial Officer and Secretary

May 26, 2026

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Cover

May 19, 2026

Cover [Abstract]

Document Type

8-K/A

Amendment Flag

false

Document Period End Date

May 19, 2026

Entity File Number

001-40363

Entity Registrant Name

TRANSCODE

THERAPEUTICS, INC.

Entity Central Index Key

0001829635

Entity Tax Identification Number

81-1065054

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Liberty Square

Entity Address, Address Line Two

#2382

Entity Address, City or Town

Boston

Entity Address, State or Province

Entity Address, Postal Zip Code

02109

City Area Code

857

Local Phone Number

837-3099

Written Communications

false

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

RNAZ

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration